Biallelic mutations in the RPE65 gene are associated with inherited retinal degenerations/dystrophies (IRD) and disrupt the visual cycle, leading to loss of vision. A new adenoviral vector-based gene therapy surgically delivered to retinal cells provides normal human RPE65 protein that can restore the visual cycle and some vision. NAME Voretigene Neparvovec-rzyl (Luxturna)
NAME
Voretigene Neparvovec-rzyl (Luxturna)
APPROVED FOR
Biallelic RPE65 mutation-associated retinal dystrophy TYPE Live non-replicating adeno-associated virus serotype 2 vector-based gene therapy (AAV2-hRPE65v2 : 5 X 10 2 viral genomes/mL) delivered by sub-retinal injection (0.3 ml). Patient must have viable retinal cells.
MOLECULAR TARGETS
Retinal pigment epithelial 65kDa protein (RPE65)
CELLULAR TARGETS

Retinal pigment epithelial (RPE) cells
EFFECTS ON TARGETS
The neurosensory retina contains photoreceptors (rods and cones) that initiate phototransduction. Chromophores produced during the visual cycle are essential to this process. RPE cells located underneath the light-sensing photoreceptors produce RPE65 that converts all-trans-retinoid to 11-cis-retinal, a key step in regenerating the chromophore. Mutations in RPE65 lead to reduced RPE65 isomerohydrolase activity with subsequent vision loss. Sub-retinal delivery of Luxturna transduces some RPE cells with a cDNA encoding normal human RPE65 protein, making it possible to restore the visual cycle.
DEVELOPED BY
Spark Therapeutics
References for further reading are available with this article online: www.cell.com/S0092-8674 (18) 
